Rare Diseases Symptoms Automatic Extraction
Home
A random Abstract
Our Project
Our Team
Statin treatment rescues FGFR3 skeletal dysplasia phenotypes.
[achondroplasia]
Gain-of-function
mutations
in
the
fibroblast
growth
factor
receptor
3
gene
(
FGFR
3
)
result
in
skeletal
dysplasias
,
such
as
thanatophoric
dysplasia
and
achondroplasia
(
ACH
)
.
The
lack
of
disease
models
using
human
cells
has
hampered
the
identification
of
a
clinically
effective
treatment
for
these
diseases
.
Here
we
show
that
statin
treatment
can
rescue
patient-
specific
induced
pluripotent
stem
cell
(
iPSC
)
models
and
a
mouse
model
of
FGFR
3
skeletal
dysplasia
.
We
converted
fibroblasts
from
thanatophoric
dysplasia
type
I
(
TD
1
)
and
ACH
patients
into
iPSCs
.
The
chondrogenic
differentiation
of
TD
1
iPSCs
and
ACH
iPSCs
resulted
in
the
formation
of
degraded
cartilage
.
We
found
that
statins
could
correct
the
degraded
cartilage
in
both
chondrogenically
differentiated
TD
1
and
ACH
iPSCs
.
Treatment
of
ACH
model
mice
with
statin
led
to
a
significant
recovery
of
bone
growth
.
These
results
suggest
that
statins
could
represent
a
medical
treatment
for
infants
and
children
with
TD
1
and
ACH
.
Diseases
Validation
Diseases presenting
"growth factor receptor"
symptom
achondroplasia
aromatase deficiency
cholangiocarcinoma
dedifferentiated liposarcoma
esophageal adenocarcinoma
esophageal carcinoma
esophageal squamous cell carcinoma
kallmann syndrome
lymphangioleiomyomatosis
oral submucous fibrosis
proteus syndrome
severe combined immunodeficiency
wiskott-aldrich syndrome
You can validate or delete this automatically detected symptom
Validate the Symptom
Delete the Symptom